Abstract-This brief commentary is based on the debate that took part in May 2010 in New York. We describe the initial difficulties experienced in early genome-wide association studies of blood pressure and hypertension, as well as strategic developments, including large meta-analyses and sampling from the extremes of blood pressure distribution. The reasons for negative attitudes toward the genome-wide association studies include their nonhypothesis-driven character and the need for very large sample sizes. Nevertheless, we describe published successes, which include 13 single nucleotide polymorphisms/loci associated with blood pressure and hypertension at PϽ5ϫ10
T he epidemiological data show that hypertension arises from a combination of genetic and environmental factors. The heritability of blood pressure (BP), which is defined as the fraction of BP variance contributed by genetic determinants, has been variably estimated between 30% and 50%. 1 Moreover, sibling recurrence risk, which is defined as a relative risk of hypertension when a sibling is affected, has been estimated at 2.5 to 3.5. 2 The human genome project celebrated its 10th birthday in April 2010. 3 The decade from 2000 to 2010 was characterized by breathtaking acceleration in genome science, which includes the HapMap project that produced a remarkable catalogue of common variation in the genome. 4 This, in turn, paved the way for genome-wide association studies (GWASs). These studies use Յ1 million or more directly genotyped single nucleotide polymorphisms (SNPs) to scan the entire genome in thousands of individuals, in cases and controls or population samples to find genome-wide significant associations between an SNP and a disease or quantitative trait. 5 Hypertension was one of the first traits studied under GWAS. Human essential or primary hypertension is highly prevalent; it is a classic quantitative trait with both systolic and diastolic pressures being normally distributed in the general population. The first large collaborative GWAS for hypertension was performed by the Wellcome Trust Case Control Consortium and was published in 2007 6 ; this study revealed no SNPs crossing the experimental threshold of significance established at PϽ10 Ϫ7 . Eight further individual GWASs for BP or hypertension have been published since. 7 Ϫ7 . This gene encodes ATPase calcium ion transporting plasma membrane 1, a protein known to be involved in calcium homeostasis. 14 In 2009, 2 large-scale meta-analyses of GWAS for BP and hypertension were published. 15, 16 These were the Global BPGen Consortium and the Cohorts for Heart and Ageing Research in Genome Epidemiology BP Consortium, which meta-analyzed GWAS data from 34 433 and 29 136 individuals, respectively. 15, 16 Both consortia identified genome-wide significant (PϽ5ϫ10 Ϫ8 ) associations at 8 loci, with 3 of these loci being common to both studies ( Figure) . Two of 13 genomic regions identified by these 2 meta-analyses contain genes that have been implicated previously in hypertension susceptibility. These include the chromosome 1p32 with atrial natriuretic peptide A and B-type natriuretic peptide genes (NPPA and NPPB) and chromosome 10q24 with a strong candidate gene, the CYP17A1. Mutations in the latter gene cause 17-␣-hydroxylase congenital adrenal hyperplasia, an autosomal recessive mineralocorticoid hypertension.
Despite the above successes (robust associations between Ն13 SNPs and BP), critics of the GWAS strategy mention that each SNP explains only a very small proportion of BP variance, Ϸ1.0 mm Hg per allele of systolic BP and 0.5 mm Hg per allele of diastolic BP. This leads to further criticisms that only a modest fraction of heritability has been explained so far despite large amounts of money being funneled into GWASs.
Before we address these criticisms, it is worth considering their origins. First, GWAS, as all other forms of genetic mapping, turns hypothesis-driven research on its head, because it is based on the theory that systematic genome-wide study of DNA variation will lead us to disease genes. Because the majority of research training centers revolves around hypothesis-driven research, some animosity against GWAS is predictable.
Second, to be successful, these studies require very large sample sizes with very stringent levels of statistical significance. This, in turn, requires big collaborative ventures with Ն10 000 participants. These are new ways of conducting biomedical research, and not surprisingly it takes time for our research community to adjust.
It should be noted that, whereas individual SNPs indeed have very small effects, their aggregate effect on BP is significant and able to produce meaningful population changes in risk. 15 Moreover, an important and positive message resulting from meta-analyses published thus far is that there are many more common variants associated with BP that remain to be discovered. 17 In light of these conclusions, it is also relatively easy to predict the bright future for GWAS and related studies in hypertension. The term "mega-analysis" has been coined to describe the ongoing even larger meta-analyses, such as the International Consortium for Blood Pressure-GWAS, 17 which is due to report shortly. This study combines all of the cohorts from the Global BPGen and Cohorts for Heart and Ageing Research in Genome Epidemiology consortia with some additional cohorts and will present data from Ͼ70 000 individuals. Parallel efforts target individuals with extreme BP and cardiovascular risk phenotypes, and the first successful study of this kind has reported recently. 18 The commercially available chips used for GWASs have increasing structural variation content. However, a careful analysis of these copy number variants in large meta-analyses is awaited; the Wellcome Trust Case Control Consortium recently found no association between copy number variant using a bespoke chip and hypertension. 19 In contrast, Chen et al, 20 using a new statistical model to calculate copy numbers from previously published SNP genome-wide data from the Wellcome Trust Case Control Consortium Study, 6 did indeed find 7 new copy number variant-associated hypertensive loci. This study could provide an alternative statistical approach to discovering new associated loci of human diseases using already published genome-wide SNP data. Resequencing using highthroughput (next generation) sequencing technologies of cases and controls will be increasingly used for fine mapping and the identification of causal variants. It appears that sampling from extremes of BP distribution might be one way forward when using these new technologies. In summary, the biggest gains from the GWAS strategy include our improved understanding of pathophysiology of hypertension; as in most cases, genes and regions identified are novel and fill critical gaps in our current knowledge. Moreover, a common noncoding SNP might have a small effect, but the underlying gene/protein/mechanism might become a very important drug target. Lastly, GWAS strategy brings special opportunities for physician scientists. Rather than seeking a new twist on a well-studied pathway or asking whether findings in a model organism are relevant to human disease, we can explore dozens of genes proven by GWAS to be relevant to human hypertension. The real challenge will be to develop appropriate functional studies to take us from GWAS and related methodologies to useful clinical applications. In their defense of GWA studies of hypertension, Dominiczak and Munroe present most of the same tenuous arguments that have been used to justify these kinds of enormously expensive efforts in the past. All of these arguments and their weaknesses have been addressed in my original position piece and will not be repeated here. Nevertheless, despite our distinctly different opinions on the subject, it appears that we also share some common ground. To their credit, Dominiczak and Munroe refrain from putting forth one of the most frequently exaggerated and hollow claims used to justify GWA studies: the false promise that such studies will lead to the development of genetic profiles useful for predicting an individual's risk for hypertension. We also share common ground in our optimism for the potential of next-generation sequencing technology to help move us beyond the limitations of GWA studies, even though our ideas on how best to apply this technology may differ in some important aspects. With respect to the assertion by my esteemed opponents that the criticisms of GWAS are motivated by animosity toward nonhypothesis-driven research and "big" scientific ventures, I respectfully disagree. I believe that nonhypothesis-driven fishing expeditions involving largescale collaborative research efforts can be very productive provided that the nets they cast do not contain as many large holes as GWA studies.
"As for the future, your task is not to foresee, but to enable it." --Antoine de Saint-Exupèry, The Wisdom of the Sands
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